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Abstract
Purpose: Lip cancer can be treated by surgery, external radiotherapy, and/or brachytherapy (BT). In recent years,
BT has become increasingly favored for this type of cancer. The aim of the present study was to analyze local control
and survival of patients treated at our institution between July 1989 and June 2008. 
Material and methods: We performed a retrospective study of 121 patients (109 males and 12 females) who under-
went lip cancer brachytherapy from July 1989 to June 2008. Median age was 67 years and median follow-up was 
31.8 months (range 20-188 months). Out of 121 patients, 100 (82.6%) were treated with low dose rate (LDR) BT while
the remaining 21 patients (17.4%) received high dose rate (HDR) BT. 
Results: The most common cell type was squamous cell carcinoma (115 cases; 95%) and most tumors were located
on the lower lip (107 patients; 88.4%). Most cases were either stage T1 (62 patients; 51.2%), or T2 (44 cases; 36.4%). After
15 years of follow-up, overall survival was 89.5%, cause-specific survival 97.8%, and disease-free survival 86.6%. Local,
regional, and distant control at 15 years were 90%, 92%, and 98.8%, respectively. Grade 3 mucosal toxicity was observed
in 23% of patients treated with LDR compared to 33% of HDR patients, and grade 4 mucosal toxicity in 9% versus 0%
in the HDR group. 
Conclusions: Our findings confirm that brachytherapy is an effective treatment for lip cancer. The results from our
series are in line with those published elsewhere. Based on our limited data, HDR appears to be equally as good as LDR,
although this needs to be confirmed by further studies.
J Contemp Brachyther 2010; 2, 1:  9-13
Key words: lip cancer, brachytherapy, radiotherapy dosage.
Purpose
In the United States, lip cancer is among the most com-
mon type of head and neck skin cancers, with the annual
incidence estimation of 1.8 cases per 100 000 inhabitants.
Numerous etiological factors such as: alcohol intake, ina-
dequate oral hygiene, tobacco use, sun exposure, and pre-
cancerous lesions, have been related to lip cancer, although
tobacco use (especially pipes) and sun exposure have the
strongest association with this disease.  Most patients are
men, with a median age of 65 [1]. In 95% of cases, the
tumor is located on the lower lip. More than 90% of lip can-
cers are squamous cell carcinomas while approximately
10% are basal cell carcinomas. Other histological types are
exceptional [2]. 
Lip cancer is a slow-growing, localized cancer often
diagnosed at an early stage; as a result, survival rates are
usually quite high. At diagnosis, only 5-10% of patients
have nodal involvement, usually in cases with undiffer-
entiated cells and advanced stages [3, 4]. Distant metas-
tases are infrequent and associated with very large tumors
that are not locally controlled. Prognosis depends on the
size of primary lesion, nodal involvement, perineural and
lymphovascular invasion, and age, with a worse progno-
sis in younger patients [5]. Five year survival is 90-95% for
T1 tumors, and 75-85% for T2, with a drastic drop off in
survival for patients at stage T3-T4 [6]. 
Treatment typically includes radiotherapy (brachythe-
rapy in general) and/or surgery. For a long time, low dose
rate (LDR) brachytherapy was the treatment of choice,
although high dose rate (HDR) BT was recently introduced.
Brachytherapy as a treatment modality is recommended in
up to 90% of lip tumor cases, with excellent results in local
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main purpose of this retrospective study was to analyze
our results in terms of local control and survival in
brachytherapy patients treated at our institution between
July 1989 and June 2008. 
Material and methods
From July 1989 to June 2008, a total of 121 patients diag-
nosed with lip cancer were treated with brachytherapy,
with a median follow up of 31.8 months (range 20-188
months). Tumor staging was determined by clinical histo-
ry, physical examination, histological diagnosis, and
metastatic extension of the disease. The patient and tumor
characteristics  and treatment of 121 patients are described
in Table 2. Out of 121 patients in our series, 109 were males
(90.1%) and 12 females (9.9%). The median age at the
beginning of treatment was 67 years. The most common
tumor type was squamous cell carcinoma (115 cases; 95%),
followed by basal cell carcinoma (3 cases; 2.5%), and cys-
tic adenoid carcinoma (1 case; 0.8%). In 2 cases (1.7%) his-
tological results were not available. Most tumors were
located on the lower lip  (107 patients; 88.4%), followed by
the upper lip (8 cases; 6.6%), and commissure of lip (4 cases;
3.3%). Tumor staging was performed according to the
TNM classification system, with 5 patients (4.1%) at stage
Tis, 62 cases (51.2%) at stage T1, 44 (36.4%) stage T2, 
3 cases (2.5%) stage T4, and in 7 patients (5.8%) the stage
was unknown. 
BT with guide needles was performed in most cases 
(109 patients; 90.1%) while the remaining 12 patients (9.9%)
were treated with plastic tubes. A total of 21 patients
(17.4%) received high dose rate (HDR) brachytherapy
while 100 patients (82.6%) underwent low dose rate (LDR)
procedures with Iridium-192 (I-192) as radionuclide.
Dosimetry was adapted from the Paris System with some
modifications depending on the location. The dose varied
between 45 Gy and 50 Gy for HDR treatments and between
60 Gy and 70 Gy for LDR. 
Results
Survival analysis was performed for the whole series.
Differential analysis between LDR and HDR was not pos-
sible due to the limited number of patients treated by HDR.
At 15 years, overall survival was 89.5%, cause-specific sur-
vival 97.8% and disease-free survival 86.6% (Figs. 1-3).
Local, regional, and distant control, were 90%, 92%, and
98.8%, respectively (Figs. 4-6).
Toxicity was scored according to the Radiation Thera-
py Oncology Group/European Organization for Research
Author # Cases (stage) BT Dose 5 year (10 year*) local failure rates
All T1 T2 T3 T4 PSR
Gerbaulet et al., 316 (T1-T4) Ra206 4.2% 0% 2.1% 7.7% 4/6
1978 [10] Ir192
Pigneux et al., 93 Ir192 4.5% 2.2% 4.3% 5.2% –
1979 [23] 65-75 Gy
Mazeron et al., 1896 (T1-T4) 629 Ra206 10.9% 8.3% 10.8% 7/12
1983 [21] Cs137 3.4% 1.6% 3.4% 10% 1/15
1267 Ir192 
Cowen et al., 248 Ir192 4% 3.4% 5.4% 3.7% 6/9
1990 [8] 60-81 Gy
Orrechia et al., 47 (T1-T2) Ir192 6.4% 6.4% – –
1991 [22] 60-80 Gy
Van Limbergen  2794 (T1-T4) Ir192 6% 5% 8.2% 19% 0/24 17%
et al., 1993 [16] PSR 40-90 Gy 10%* 7.5% 12% 30% 23%
Cs137
Cerezo et al., 117 XRT (± surgery) 4% 4% 6% -
1993 [19]
Gerbaulet et al., 231 Ir192 5.6% na na na na
1994 [11] 70-85 Gy
Beauvois et al., 237 (T1-T4) Ir192 5% –
1994 [7] 65-68 Gy 8%*
Farrus et al., 72 (T1-T3) PSR Ir192 11% 10% 7% 25% – 13%
1996 [9] 62-67 Gy
Visscher et al., 108 (T1-T3) Ir192 48-70 Gy 4.6% 1.1% 23.5% 0/2
1996 [17] XRT, Electrons, 
photons
Tombolini et al., 57 (T1-T3) Ir192 10% na na na –
1998 [14] 62Gy
Table 1. PSA level before and after salvage HDR-BT
XRT – indicates external beam radiation therapy, na – not available, BT – brachytherapy, PSR – post surgical recurrences
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and Treatment of Cancer (RTOG/EORTC) scales. Grade 3
mucosal toxicity was observed in 23% of patients treated
with LDR compared to 33% of the HDR group, and grade
4 mucosal toxicity in 9% of LDR cases versus 0% of HDR
patients. HDR and LDR BT showed similar results in terms
of chronic fibrosis, telangiectasias, chronic alopecia and
atrophy, although HDR was slightly superior to LDR.
None of these differences, however, were significant as
only a small percentage of cases experience any of these
alterations (Grade 1 or 2 in all cases). 
Discussion
Lip cancer is a common malignancy of the head and
neck region and is frequently diagnosed at an early stage.
A number of modalities, including surgery, external radio-
therapy, and brachytherapy are all very successful in treat-
ment of these lesions. However, because numerous differ-
ent treatments have shown to provide good results,
considerable uncertainty exists with regards to the treat-
ment of choice.
At present, brachytherapy is one of the most important
therapeutic treatments for lip cancer, because it can be used
as a monotherapy, after surgery, or as a localized boost
after external beam radiation therapy. Experience has
shown that a high tumor dose is required to achieve local
control [18]. The main treatment aim is to achieve tumor
control while limiting toxicity and preserving function 
to the maximum extent possible. In stage T2-T3 cancers,
surgery does not always completely eliminate the tumor,
even with a surgical margin of safety, as evidenced by 
the incidence of local recurrences described in various stud-
ies [19-23] (Table 1). Brachytherapy offers numerous
advantages, including  high localized dose with rapid 
fall-off, and short overall treatment duration. The primary
tumor volume receives a total dose that cannot be deliv-
ered by external beam radiotherapy alone, and rapid fall-
off allows sparing of critical normal tissues.
For lip cancer, especially in early stages, results show
that brachytherapy is similar to surgery in terms of local
control and survival. Considerable experience has been
accumulated with LDR brachytherapy. Gerbaulet et al. [11]
presented long-term results of 231 patients treated with
LDR I-192 brachytherapy, reporting a 94.4% local control
rate. Beauvois et al. [7] reviewed 237 patients treated with
LDR and found a 95%  local control rate at 5 years. Urraca
et al. [15] performed a retrospective analysis of overall sur-
vival in 66 patients treated with LDR brachytherapy, report-
ing 2- and 5-year survival rates of 93% and 73%, respectively. 
The use of HDR brachytherapy is becoming more pop-
ular in the treatment of lip cancer. It offers the advantage
of optimizing dose distribution by varying dwell times.
Guinot et al. [12] retrospectively evaluated 39 patients 
treated with HDR (40.5-45 Gy), with a mean follow-up of
18 months. These authors reported an overall survival of
91% and local control rates of 100% for stage T1 tumors,
Patient and treatment characteristics (%)
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HDR (45-50 Gy) 17.4%
LDR (60-70 Gy) 82.6%
Table 2. Clinical characteristics of patients
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83% in stage T2, and 75% in stage T4. The authors con-
cluded that HDR is at least as effective and safe as LDR
brachytherapy in treating small and intermediate lip car-
cinomas.
However, aside from the above-mentioned studies, rela-
tively few investigations have been published concerning
HDR lip cancer treatment. Those available include limited
number of patients and lack long-term follow-up. In our
study, only 21 patients (17.4%) received HDR brachythe-
rapy, making it  impossible to perform a differential analy-
sis between LDR and HDR. The lack of large, long-term
studies makes it difficult to define the effectiveness of HDR
in terms of local control, survival, and cosmetic and func-
tional results. Likewise, it is not yet possible to establish the
optimal total dose, number of fractions, and dose per frac-
tion. 
Conclusions
In conclusion, the results of the present study confirm
brachytherapy as an effective treatment for lip cancer with
results comparable to other treatment modalities. 
The results from our centre are in line with those published
elsewhere. Moreover, HDR appears to be as good as 
LDR in treating lip carcinomas, however this can only be
confirmed by more comprehensive long-term study.
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